









Markets
/
Stocks
/
nasdaq-notv
/

Inotiv Inc

NOTV

0.418USD

+0.028+7.26%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

14.37MMarket Cap

LossP/E TTM



Inotiv Inc

0.418

+0.028+7.26%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Inotiv Inc

Currency: USD Updated: 2026-02-06

Key Insights

Inotiv Inc's fundamentals are relatively stable, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 146 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.83.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Inotiv Inc's Score

Industry at a Glance

Industry Ranking

146 / 392

Overall Ranking

291 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Inotiv Inc Highlights

StrengthsRisks

Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.

Overvalued

The company’s latest PE is -0.20, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 8.26M shares, decreasing 32.19% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 79.45K shares of this stock.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

4.833

Target Price

+986.14%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Inotiv Inc is 7.07, ranking 162 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 138.14M, representing a year-over-year increase of 5.92%, while its net profit experienced a year-over-year increase of 54.73%.

Score

Industry at a Glance

Previous score

7.07

Change



Financials

4.40

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

5.31

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.29

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.35

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Inotiv Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Inotiv Inc is 7.85, ranking 77 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.20, which is -6.77% below the recent high of -0.18 and -4236.50% above the recent low of -8.58.

Score

Industry at a Glance

Previous score

7.85

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 146/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Inotiv Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 3.00, with a high of 9.00 and a low of 2.50.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

4.833

Target Price

+986.14%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Inotiv Inc

NOTV

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Inotiv Inc is 4.99, ranking 336 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.57 and the support level at 0.32, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.88

Change

0.11

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.011

Sell

RSI(14)

29.624

Sell

STOCH(KDJ)(9,3,3)

17.288

Oversold

ATR(14)

0.051

High Vlolatility

CCI(14)

-119.046

Sell

Williams %R

82.232

Oversold

TRIX(12,20)

-1.267

Sell

StochRSI(14)

57.177

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.447

Sell

MA10

0.483

Sell

MA20

0.531

Sell

MA50

0.645

Sell

MA100

0.958

Sell

MA200

1.492

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Inotiv Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 24.01%, representing a quarter-over-quarter decrease of 6.52%. The largest institutional shareholder is The Vanguard, holding a total of 1.39M shares, representing 4.04% of shares outstanding, with 7.42% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

1.40M

+1.51%

Leasure (Robert Jr.)

1.24M

+52.90%

Balyasny Asset Management LP

985.74K

-40.43%

Sagartz (John E)

708.32K

+4.42%

GSA Capital Partners LLP

234.52K

UBS Financial Services, Inc.

314.55K

+13.06%

Hardy (Adrian)

400.78K

+6.65%

Renaissance Technologies LLC

Star Investors

359.76K

-9.60%

Massar Capital Management, LP

350.00K

Vantage Point Financial, LLC.

336.55K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Inotiv Inc is 1.63, ranking 299 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 4.19. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Inotiv Inc’s latest ESG disclosure is at an average level in the Biotechnology & Medical Research industry, showing no material impact on overall risk.